Cargando…

Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryman, Josiah, Weaver, Jessica, Hu, Tianyan, Weinberger, Daniel M., Yee, Ka Lai, Sachs, Jeffrey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640717/
https://www.ncbi.nlm.nih.gov/pubmed/36344529
http://dx.doi.org/10.1038/s41541-022-00538-1
_version_ 1784825921532854272
author Ryman, Josiah
Weaver, Jessica
Hu, Tianyan
Weinberger, Daniel M.
Yee, Ka Lai
Sachs, Jeffrey R.
author_facet Ryman, Josiah
Weaver, Jessica
Hu, Tianyan
Weinberger, Daniel M.
Yee, Ka Lai
Sachs, Jeffrey R.
author_sort Ryman, Josiah
collection PubMed
description The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could impact effectiveness. Simulated reverse cumulative distribution curves were generated using published serotype-specific IgG concentrations with placebo or PCV7. This was combined with the published estimates of serotype-specific vaccine effectiveness of PCV7 against invasive pneumococcal disease to estimate the protective antibody concentration for each serotype in PCV7. Then, based on the published serotype-specific IgG concentrations in PCV13 recipients, reverse cumulative distribution curves were generated for the serotypes shared between PCV13 and PCV7. These estimated protective antibody concentration values were then used to predict the vaccine effectiveness of PCV13. The results were compared to published aggregate values for vaccine effectiveness. The aggregate median predicted vaccine effectiveness values were similar to previously reported observed values for the United Kingdom (93% versus 90%), Australia (71% versus 70%), and Germany (91% versus 90%). These results demonstrate that IgG concentrations of next-generation PCVs can be used to generate reliable estimates of vaccine effectiveness for serotypes shared with established PCVs.
format Online
Article
Text
id pubmed-9640717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96407172022-11-15 Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data Ryman, Josiah Weaver, Jessica Hu, Tianyan Weinberger, Daniel M. Yee, Ka Lai Sachs, Jeffrey R. NPJ Vaccines Article The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could impact effectiveness. Simulated reverse cumulative distribution curves were generated using published serotype-specific IgG concentrations with placebo or PCV7. This was combined with the published estimates of serotype-specific vaccine effectiveness of PCV7 against invasive pneumococcal disease to estimate the protective antibody concentration for each serotype in PCV7. Then, based on the published serotype-specific IgG concentrations in PCV13 recipients, reverse cumulative distribution curves were generated for the serotypes shared between PCV13 and PCV7. These estimated protective antibody concentration values were then used to predict the vaccine effectiveness of PCV13. The results were compared to published aggregate values for vaccine effectiveness. The aggregate median predicted vaccine effectiveness values were similar to previously reported observed values for the United Kingdom (93% versus 90%), Australia (71% versus 70%), and Germany (91% versus 90%). These results demonstrate that IgG concentrations of next-generation PCVs can be used to generate reliable estimates of vaccine effectiveness for serotypes shared with established PCVs. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640717/ /pubmed/36344529 http://dx.doi.org/10.1038/s41541-022-00538-1 Text en © Merck & Co., Inc., Rahway, NJ, USA and its affiliates 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ryman, Josiah
Weaver, Jessica
Hu, Tianyan
Weinberger, Daniel M.
Yee, Ka Lai
Sachs, Jeffrey R.
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title_full Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title_fullStr Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title_full_unstemmed Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title_short Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
title_sort predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640717/
https://www.ncbi.nlm.nih.gov/pubmed/36344529
http://dx.doi.org/10.1038/s41541-022-00538-1
work_keys_str_mv AT rymanjosiah predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata
AT weaverjessica predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata
AT hutianyan predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata
AT weinbergerdanielm predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata
AT yeekalai predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata
AT sachsjeffreyr predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata